But wasn't Itolizumab already approved in India (in 2013?) for treating plaque psoriasis? If so, that's a bit different from our situation as we 're not approved for anything yet. I'd imagine trial design for a 2nd indication is much simpler.

In hindsight, I wonder how things would be different if CYDY did a small (e.g. 20-25 patients ) phase 1 severe/critical trail back in late March/early April. Could quick positive results for such a trial have powered greater enrollment in larger subsequent trials that would all be completed by now?